916P - Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)
Autor: | de Wit, R., Kulkarni, G.S., Uchio, E., Boormans, J.L., Roumiguié, M., Krieger, L.E.M., Singer, E.A., Bajorin, D.F., Kamat, A.M., Grivas, P., Seo, H.K., Nishiyama, H., Konety, B.R., Saretsky, T., Li, H., Nam, K., Sbar, E., Balar, A.V. |
---|---|
Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v364-v365 |
Databáze: | ScienceDirect |
Externí odkaz: |